April 21, 2014 Bruce Goldfarb Quoted in The New York Times
To help influence the outcome of that bet, Mr. Ackman has lobbied members of Congress and regulators to investigate the company, a move that has helped to push down the value of the stock.
“What’s unusual is that we’re talking about investors who are outsiders — the outsiders are potentially becoming insiders here by teaming up with Valeant,” said Bruce H. Goldfarb, president of Okapi Partners, a proxy solicitor.
For Valeant, already among the most acquisitive health care companies today, a deal for Allergan would be its largest yet.
Unusual Hostile Bid for Maker of Botox [New York Times]